Prof. Katharina Ribbeck speaks with New York Times reporter Nina Agrawal about her research studying the health and medical benefits of mucus. “Ribbeck’s research has shown that the sugars on mucins can effectively switch off mechanisms that the bacteria involved in strep throat or cholera, for example, or fungus in a yeast infection, use to go from innocuous to harmful,” explains Agrawal.
MIT researchers have discovered a protein found in human sweat that holds antimicrobial properties and can “inhibit the growth of the bacteria that causes Lyme disease,” reports Matt Fortin for NENC. The team believes this “type of protein could be put into a topical cream to make something called ‘Lyme Block’ – like sunblock, but for preventing Lyme.” "Ideally what we would love to do is give people more control over their own risk," says Principal Research Scientist Michal Tal. "And really try to develop this into a possible preventative that you could put on repellant or sunblock to protect against other elements of the outdoors that you could also protect yourself against Lyme."
Prof. Katharina Ribbeck speaks with Christopher Intagliata of Scientific American’s “Science Quickly” podcast about her research exploring how mucus can treat and prevent disease. “The basic building blocks of mucus that give mucus its gooey nature are these threadlike molecules—they look like tiny bottlebrushes—that display lots and lots of sugar molecules on their backbone,” explains Ribbeck. “And these sugar molecules—we call them glycans—interact with molecules from the immune system and microbes directly. And the exact configuration and density of these sugar molecules is really important for health.”
Researchers from MIT and elsewhere have isolated a “protein in human sweat that protects against Lyme disease,” reports Matthew Rozsa for Salon. The researchers believe that if “properly harnessed the protein could form the basis of skin creams that either prevent the disease or treat especially persistent infections,” writes Rosza.
Graduate student Lauren “Ren” Ramlan programmed Doom, an iD software video game, to run on a display made from E.coli cells, reports Andrew Paul for Popular Science. For the project to work, “Ramlan first grew cells within a 32×48 1-bit well plate, then connected the makeshift screen to a controller capable of processing and translating binary code into the ‘addition or omission of a repressor controlling the fluorescence of the cells,’” writes Paul. “Basically, Ramlan swapped a traditional screen’s tiny light diodes for glowing bacterial cells."
MIT researchers have “used an algorithm to sort through millions of genomes to find new, rare types of CRISPR systems that could eventually be adapted into genome-editing tools,” writes Sara Reardon for Nature. “We are just amazed at the diversity of CRISPR systems,” says Prof. Feng Zhang. “Doing this analysis kind of allows us to kill two birds with one stone: both study biology and also potentially find useful things.”
Researchers from MIT and elsewhere have “genetically engineered bacteria to efficiently turn plastic waste into useful chemicals,” reports Aristos Georgiou for Newsweek. MIT Prof. James Collins and University of Illinois Urbana-Champaign Prof. Ting Lu explain that they see two potential applications for their work. "In the former case, plastic waste collected from oceans and landfills would be transported to a facility where it would be bioprocessed with engineered microbes,” they note. “In our latter scenario, these microbes could be deployed directly in lands or oceans to bio-transform plastic debris in situ.”
Ginkgo Bioworks, a biotech company founded by Jason Kelly BS ’03, PhD ’08, Reshma Shetty PhD ‘08, Barry Canton PhD ’08, Austin Che PhD ’08 and Professor Tom Knight, is working to develop synthetic fragrances, reports Scott Kirsner for The Boston Globe.
Researchers at the McGovern and Broad Institutes have developed a bacterial "nanosyringe" that can inject large proteins into specific cells in the body, which could lead to safer and more effective treatments for a variety of conditions, including cancer, reports Michael Le Page for New Scientist. “The fact that this can load a diversity of different payloads of different sizes makes it unique amongst protein delivery devices,” says graduate student Joseph Kreitz.
Ingrid Wickelgren at Scientific American highlights a new study from researchers at the McGovern and Broad Institutes, in which they used a bacterial ‘nanosyringe’ to inject large proteins into human cells. “The syringe technology also holds promise for treating cancer because it can be engineered to attach to receptors on certain cancer cells,” writes Wickelgren.
Research from Synlogic, a biotech company founded by Profs James Collins and Timothy Lu, has found that it’s the company’s engineered bacteria could provide some benefit to patients with a rare genetic disease, reports Emily Mullin for Wired. “Similar to how you might program a computer, we can tinker with the DNA of bacteria and have them do things like produce a drug at the right time and the right place, or in this case, break down a toxic metabolite,” says Lu.
Forbes contributor David Bressan writes that a new study by MIT researchers proposes that oxygen began accumulating in early Earth’s atmosphere due to interactions between marine microbes and minerals in ocean sediments. The researchers hypothesize that “these interactions helped prevent oxygen from being consumed, setting off a self-amplifying process where more and more oxygen was made available to accumulate in the atmosphere,” writes Bressan.
New York Times reporter Veronique Greenwood writes that Prof. Tami Lieberman examined the human skin and found that each pore had a single variety of Cutibacterium acnes bacteria living inside. “Each person’s skin had a unique combination of strains, but what surprised the researchers most was that each pore housed a single variety of C. acnes,” writes Greenwood. “The pores were different from their neighbors, too — there was no clear pattern uniting the pores of the left cheek or forehead across the volunteers, for instance.”
Researchers from MIT have developed a 3-D printable ink made from bacterial cells that can release anti-cancer drugs or remove toxins from the environment, reports Carissa Wong for New Scientist. This is the first of its kind,” says research affiliate Avinash Manjula-Basavanna. “A living ink that can respond to the environment. We have repurposed the matrix that these bacteria normally utilise as a shielding material to form a bio-ink.”
New York Times reporter Steve Lohr spotlights the origin and history of MIT startup Gingko Bioworks, a synthetic biology company founded with a “shared belief that biology could be made more like computing with reusable code and standard tools instead of the bespoke experiments of traditional biology." Jason Kelly ’03, PhD ’08, one of the founders of MIT startup Ginkgo Bioworks and the company’s chief executive, explains that “the ultimate goal for Ginkgo is to make it as easy to program a cell as it is to program a computer.”